Spasticity Assessment & Management
Spasticity is a velocity-dependent increase in tonic stretch reflexes, representing one component of the upper motor neuron (UMN) syndrome. It is one of the most common sequelae encountered in neurorehabilitation, arising from stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, and cerebral palsy. A nuanced understanding of spasticity management requires recognizing that not all spasticity is harmful — some patients rely on it functionally — and that treatment should be goal-directed, addressing specific functional limitations or complications rather than simply reducing tone for its own sake.
Bottom Line
- Not all spasticity requires treatment: Some patients use extensor spasticity functionally for standing and transfers; treat only when spasticity causes pain, contracture, hygiene difficulty, impaired function, or sleep disruption.
- Negative UMN features cause more disability than positive features: Weakness, loss of dexterity, and fatigue are often more limiting than spasticity itself.
- Goal-directed treatment is essential: Define clear, patient-centered goals before initiating any intervention — “reduce spasticity” is not a goal; “improve hand hygiene” or “reduce shoulder pain” are goals.
- Address aggravating factors first: UTI, constipation, pain, pressure ulcers, and poor positioning all worsen spasticity and may be easily correctable.
- Botulinum toxin is first-line for focal spasticity: Effective and well-tolerated; must be combined with rehabilitation for optimal outcomes.
- Intrathecal baclofen is the treatment of choice for severe generalized spasticity: Particularly effective for lower limb spasticity; withdrawal syndrome is life-threatening.
Upper Motor Neuron Syndrome
Spasticity is best understood within the broader context of the upper motor neuron syndrome. The UMN syndrome encompasses both positive (exaggerated) and negative (deficit) phenomena, and effective management requires addressing both.
| Positive Features (Increased Activity) | Negative Features (Decreased Activity) |
|---|---|
| Spasticity (velocity-dependent hypertonia) | Weakness (most functionally limiting) |
| Clonus | Loss of dexterity and fine motor control |
| Flexor and extensor spasms | Fatigue |
| Hyperreflexia | Impaired selective motor control |
| Babinski sign / extensor plantar response | Slowness of movement |
| Mass movement patterns (synergies) | Loss of postural reflexes |
| Associated reactions (involuntary movement in affected limb during effort) | |
| Dystonia (abnormal posturing) |
Key Concept: Negative Features Are More Disabling
- Patients and clinicians often focus on spasticity (a positive feature) because it is visible and measurable
- However, weakness and loss of dexterity (negative features) are the primary causes of functional disability in most patients with UMN syndrome
- Reducing spasticity pharmacologically (especially with systemic agents) can unmask weakness and worsen function
- This is why goal-directed treatment and careful assessment of the functional contribution of spasticity are essential before intervening
When to Treat Spasticity
The decision to treat spasticity should always begin with the question: Is this spasticity causing a problem, and what specific problem does the patient or caregiver want to solve?
Indications for Spasticity Treatment
- Pain: Spastic muscles and spasms cause significant pain; particularly common in shoulder adductors, hip adductors, and plantar flexors
- Contracture prevention/treatment: Sustained spasticity leads to muscle shortening, fibrosis, and fixed contractures that are difficult to reverse
- Hygiene difficulty: Clenched fist (maceration of palm skin, nail injury), adducted thighs (perineal care), flexed elbow (axillary hygiene)
- Impaired function: Spasticity interfering with walking (equinovarus foot), reaching (shoulder/elbow flexor spasticity), or hand function (finger/wrist flexor spasticity)
- Sleep disruption: Nocturnal spasms causing pain and sleep fragmentation
- Skin breakdown: Abnormal posturing leading to pressure ulcer formation
- Impaired positioning: Difficulty with wheelchair seating, splinting, or orthotic fitting
When NOT to Treat Spasticity
- Functional spasticity: Some patients with paraplegia use leg extensor spasticity to stand during transfers and to maintain standing with a frame — reducing this spasticity would impair their mobility
- Minimal symptoms: Mild spasticity detected on examination that is not causing pain, contracture, or functional limitation
- When reduction would worsen function: Always consider whether reducing tone will unmask weakness that is currently masked by spasticity
Assessment of Spasticity
Clinical Scales
| Scale | Grading | Description | Strengths | Limitations |
|---|---|---|---|---|
| Modified Ashworth Scale (MAS) | 0, 1, 1+, 2, 3, 4 | 0 = no increase in tone; 1 = slight catch and release; 1+ = slight catch + minimal resistance through <50% ROM; 2 = marked increase through most ROM; 3 = considerable increase, passive movement difficult; 4 = rigid | Most widely used; quick; easy to administer | Poor interrater reliability at grades 1 and 1+; does not distinguish velocity-dependent spasticity from rigidity or contracture; ordinal, not interval data |
| Modified Tardieu Scale (MTS) | Measures angle of catch at slow vs. fast velocity | Compares resistance at two velocities (V1 = slow, V3 = fast); spasticity angle = difference between R2 (full passive ROM at V1) and R1 (angle of catch at V3) | Better theoretical basis (tests velocity-dependence); distinguishes neural (spasticity) from non-neural (contracture) components | More complex to perform; requires goniometry; less widely adopted in clinical practice |
| Penn Spasm Frequency Scale | 0–4 | Patient-reported frequency and severity of spasms | Captures patient experience; useful for monitoring spasm-predominant presentations | Subjective; does not measure spasticity directly |
Goal-Oriented Assessment
Structured Goal Setting for Spasticity
- Use Goal Attainment Scaling (GAS) to define individualized, measurable goals before treatment
- Common goal categories:
- Passive function: Improve ease of dressing, perineal care, hand hygiene, positioning
- Active function: Improve reaching, grasping, walking pattern, transfers
- Pain reduction: Decrease spasticity-related pain at specific joints
- Prevent complications: Prevent contracture progression, reduce skin breakdown risk
- Reassess goals at each treatment visit to determine if intervention is achieving the desired outcome
Aggravating Factors
Before intensifying spasticity treatment, always search for and address aggravating factors (sometimes called “noxious stimuli”) that can dramatically worsen spasticity.
Common Aggravating Factors (“Noxious Stimuli”)
- Urinary tract infection: The most common treatable cause of acutely worsened spasticity
- Constipation/fecal impaction: Particularly important in spinal cord injury
- Pressure ulcers / skin breakdown: Any source of nociceptive input below the level of the UMN lesion
- Ingrown toenails, tight shoes/clothing, poorly fitting orthoses
- Pain from any source: Fractures, DVT, heterotopic ossification
- Poor positioning: Inadequate wheelchair seating or bed positioning
- Emotional stress, anxiety, fatigue
- Temperature extremes
- Clinical pearl: A patient with a sudden increase in spasticity should be evaluated for an underlying medical cause before adjusting antispasticity medications
Oral Antispasticity Medications
| Medication | Mechanism | Typical Dose | Advantages | Disadvantages/Side Effects |
|---|---|---|---|---|
| Baclofen | GABA-B receptor agonist; presynaptic inhibition in spinal cord | 5 mg TID, titrate to 20 mg TID (max 80 mg/day) | Most commonly used; effective for spinal spasticity; available generic | Sedation is the major limitation; weakness; withdrawal seizures if discontinued abruptly — always taper slowly |
| Tizanidine | Alpha-2 adrenergic agonist; reduces excitatory neurotransmitter release | 2 mg TID, titrate to 8 mg TID (max 36 mg/day) | Less weakness than baclofen; less sedation at equivalent efficacy; good for nocturnal spasticity | Dry mouth, sedation, dizziness; hepatotoxicity — monitor LFTs at baseline and periodically (at 1, 3, 6 months) |
| Dantrolene | Peripheral muscle relaxant; antagonizes the ryanodine receptor (RyR1) to block calcium release from the sarcoplasmic reticulum | 25 mg daily, titrate to 100 mg QID (max 400 mg/day) | Works peripherally (no CNS sedation at therapeutic doses); useful when sedation must be avoided | Hepatotoxicity (potentially fatal — monitor LFTs closely); generalized weakness; diarrhea |
| Diazepam | GABA-A receptor positive allosteric modulator | 2 mg BID–TID, titrate as tolerated | Effective for nocturnal spasms; anxiolytic effect may be beneficial in some patients | Sedation, cognitive impairment, dependence, fall risk; long half-life; impairs motor recovery — generally avoided in rehabilitation |
| Gabapentin/Pregabalin | Calcium channel α2δ ligand; reduces excitatory neurotransmitter release | Gabapentin 300–3600 mg/day; Pregabalin 75–600 mg/day | Useful adjuncts, especially when neuropathic pain coexists with spasticity | Sedation, dizziness, peripheral edema; modest antispasticity effect when used alone |
Focal Treatments
Botulinum Toxin
Botulinum toxin injection is the treatment of choice for focal spasticity. See the dedicated topic (Botulinum Toxin for Spasticity) for comprehensive coverage of formulations, injection targets, dosing, and integration with rehabilitation.
Phenol and Alcohol Nerve Blocks
Phenol/Alcohol Nerve Blocks
- Mechanism: Chemical neurolysis — phenol (5–7% aqueous) or ethanol (50–100%) injected at nerve or motor point to destroy axons and reduce tone
- Duration: 3–12 months (longer than botulinum toxin); may be repeated
- Advantages: Lower cost than botulinum toxin; no dose ceiling; effective for large muscles; longer duration of action
- Disadvantages: Painful injection; risk of dysesthesia (burning neuropathic pain) if injected near sensory nerves; less precise than botulinum toxin
- Common targets: Obturator nerve (hip adductors), musculocutaneous nerve (elbow flexors), tibial nerve branches (plantar flexors)
- Best use: Combined with botulinum toxin when total toxin dose would otherwise be exceeded; cost-limited settings; very large muscles
Intrathecal Baclofen (ITB)
ITB delivers baclofen directly to the spinal cord via an implanted programmable pump and catheter system, achieving effective CSF drug levels at a fraction of the oral dose, thereby minimizing systemic side effects.
| Aspect | Details |
|---|---|
| Indications | Severe generalized spasticity (especially lower limbs) refractory to oral medications and focal treatments; common in spinal cord injury, MS, CP, severe stroke/TBI |
| Trial procedure | Intrathecal bolus (50–100 μg) via lumbar puncture; assess response over 4–8 hours; positive response (significant tone reduction) proceeds to pump implantation |
| Pump implantation | Surgically implanted pump in subcutaneous abdominal pocket; catheter threaded intrathecally to target level; programmable for continuous infusion ± bolus doses |
| Typical dose range | 50–1000 μg/day (compared to 30–80 mg/day oral); dose titrated over weeks to months |
| Pump refill | Every 1–6 months depending on dose and reservoir volume; percutaneous refill through pump septum |
| Battery life | 5–7 years; requires surgical pump replacement |
ITB Complications and Safety
- Catheter malfunction: The most common complication; includes catheter disconnection, kinking, migration, or occlusion; presents as acute return of spasticity
- Infection: Wound infection, meningitis; requires surgical management and possibly pump removal
- Overdose: Excessive sedation, respiratory depression, coma; treatment is supportive (ICU, ventilatory support); no specific antidote but physostigmine has been used
- Withdrawal syndrome: LIFE-THREATENING — abrupt ITB cessation causes rebound spasticity, hyperthermia, rhabdomyolysis, autonomic instability, seizures, and can be fatal; resembles neuroleptic malignant syndrome or malignant hyperthermia
- Withdrawal management: Restore intrathecal delivery as rapidly as possible; high-dose oral baclofen, benzodiazepines, and cyproheptadine as temporizing measures; ICU admission for severe cases
- Patient education: All ITB patients and caregivers must understand the signs of withdrawal and the critical importance of pump refill appointments
Surgical Interventions
- Tendon lengthening: Surgical lengthening of shortened tendons (e.g., Achilles tendon, hamstrings); provides permanent correction of fixed contracture; consider when spasticity management alone is insufficient
- Tendon transfer: Rerouting a functioning tendon to replace a paralyzed one; requires careful assessment of voluntary motor control
- Selective dorsal rhizotomy (SDR): Selective cutting of dorsal rootlets to reduce afferent input driving spasticity; primarily used in pediatric cerebral palsy; permanent reduction in spasticity; risk of weakness and sensory changes
Rehabilitation Approaches
| Intervention | Description | Evidence/Role |
|---|---|---|
| Stretching | Sustained stretch of spastic muscles; manual or with devices | Short-term reduction in spasticity; may prevent contracture progression; should be performed daily; evidence for long-term benefit is limited when used alone |
| Serial casting | Progressive casting at increasing joint angles over weeks | Effective for improving ROM in contractures, particularly ankle equinus and elbow flexion; best combined with botulinum toxin |
| Splinting/orthoses | Static or dynamic splints to maintain joint position | Maintains ROM gains achieved through other treatments; night splints for prevention; evidence for independent spasticity reduction is limited |
| Standing programs | Standing frames or tilt tables for sustained weight-bearing | Prolonged stretch to plantar flexors, hip flexors, knee flexors; may reduce lower limb spasticity; also benefits bone density and cardiovascular function |
| Functional electrical stimulation | Electrical stimulation of antagonist muscles | Reciprocal inhibition of spastic agonist; may improve voluntary activation; useful as adjunct to task-specific training |
Treatment Algorithm
Stepwise Approach to Spasticity Management
- Step 1 — Identify and address aggravating factors: UTI, constipation, pain, positioning, skin breakdown
- Step 2 — Rehabilitation baseline: Stretching, positioning, splinting, standing programs for all patients with spasticity
- Step 3 — Mild focal spasticity: Continue rehabilitation; consider adding oral agent if symptomatic
- Step 4 — Moderate focal spasticity: Botulinum toxin injections combined with intensive rehabilitation (stretching, casting, task-specific training)
- Step 5 — Moderate generalized spasticity: Oral agents (baclofen or tizanidine first-line) combined with focal treatments as needed
- Step 6 — Severe generalized spasticity (especially lower limbs): Intrathecal baclofen trial and pump implantation
- Step 7 — Fixed contracture: Surgical options (tendon lengthening, release) when conservative measures fail
- At every step: Define goals, measure outcomes, adjust treatment
References
- Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology. 1980;30(12):1303–1313.
- Sheean G, McGuire JR. Spastic hypertonia and movement disorders: pathophysiology, clinical presentation, and quantification. PM R. 2009;1(9):827–833.
- Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86(19):1818–1826.
- Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve. 2005;31(5):535–551.
- Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil. 2010;24(4):293–304.
- Francisco GE, McGuire JR. Poststroke spasticity management. Stroke. 2012;43(11):3132–3136.
- Saulino M, Ivanhoe CB, McGuire JR, et al. Best practices for intrathecal baclofen therapy: patient selection. Neuromodulation. 2016;19(6):607–615.
- Ward AB. A literature review of the pathophysiology and onset of post-stroke spasticity. Eur J Neurol. 2012;19(1):21–27.
- Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13–25.
- Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206–207.
- Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil. 2002;83(6):735–741.
- Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines. 2nd ed. London: RCP; 2018.
- Pandyan AD, Gregoric M, Barnes MP, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1-2):2–6.
- Nair KP, Marsden J. The management of spasticity in adults. BMJ. 2014;349:g4737.